|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2009-8-17
|
|
pubmed:abstractText |
Recently sulfamoyl benzamides were identified as a novel series of cannabinoid receptor ligands. Replacing the sulfonamide functionality and reversing the original carboxamide bond led to the discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB(2) agonists. Selective CB(2) agonist 31 (K(i)=2.7; CB(1)/CB(2)=190) displayed robust activity in a rodent model of postoperative pain.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
pubmed-author:BarkerWilliam MWM,
pubmed-author:BrogdonBernice LBL,
pubmed-author:CasselJoel AJA,
pubmed-author:DeHavenRobert NRN,
pubmed-author:DolleRoland ERE,
pubmed-author:DulayDoreen-Marie SDM,
pubmed-author:GreenRosalyn CRC,
pubmed-author:KoblishMichaelM,
pubmed-author:LaBudaChristopher JCJ,
pubmed-author:SaeuiChristopher TCT,
pubmed-author:SmithSteven ASA,
pubmed-author:StableyGabriel JGJ,
pubmed-author:WeaverDamian GDG,
pubmed-author:WormKarinK
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5004-8
|
|
pubmed:meshHeading |
pubmed-meshheading:19646869-Animals,
pubmed-meshheading:19646869-Anti-Inflammatory Agents,
pubmed-meshheading:19646869-Benzamides,
pubmed-meshheading:19646869-CHO Cells,
pubmed-meshheading:19646869-Cell Line,
pubmed-meshheading:19646869-Cricetinae,
pubmed-meshheading:19646869-Cricetulus,
pubmed-meshheading:19646869-Drug Discovery,
pubmed-meshheading:19646869-Humans,
pubmed-meshheading:19646869-Pain, Postoperative,
pubmed-meshheading:19646869-Rats,
pubmed-meshheading:19646869-Receptor, Cannabinoid, CB2,
pubmed-meshheading:19646869-Stereoisomerism,
pubmed-meshheading:19646869-Structure-Activity Relationship,
pubmed-meshheading:19646869-Transfection
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.
|
|
pubmed:affiliation |
Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA. kworm@adolor.com
|
|
pubmed:publicationType |
Journal Article
|
